HARBIN, China, April 29 RenhuangPharmaceuticals, Inc. (Pink Sheets: RHGP) ("Renhuang" or the "Company"), adeveloper, manufacturer and distributor of botanical products,bio-pharmaceuticals and traditional Chinese medicines ("TCM"), today announcedthe Company plans to launch Qing Re Jie Du Oral Liquid ("Qing"), a traditionalOver-the-Counter ("OTC") Chinese Medicine for the treatment of influenza ("theflu") and upper respiratory infections in June 2010.
Qing is an all-natural, plant-based traditional OTC Chinese Medicine withproven benefits in treating the flu, upper respiratory infections, and sorethroats. The Company expects Qing to generate $1.0 million to $1.5 million inrevenues in fiscal 2010.
"We have great confidence in the performance and effectiveness of ourlatest product, Qing Re Jie Du Oral Liquid, and anticipate positive marketacceptance," said Mr. Shaoming Li, the Chairman and CEO of Renhuang. "Qing'sall-natural active ingredients are effective against flu symptoms and cause noside effects associated with chemical drugs. At Renhuang, we are committed todeveloping superior products which meet the needs of our customers and we areequally committed to creating value for our shareholders. In this pursuit, wecontinue to expand our product portfolio to boost our revenue stream and fuelRenhuang's growth."
ABOUT RENHUANG PHARMACEUTICALS, INC.
Renhuang Pharmaceuticals, Inc. is engaged in the research, development,manufacturing, and distribution of botanical products, bio-pharmaceuticalproducts, and traditional Chinese medicines ("TCM"), in the People's Republicof China. All of the Company's products are produced at its threeGMP-certified production facilities in Ah City, Dongfanghong and Qingyang.The Company distributes its botanical anti-depression and nerve-regulationproducts, biopharmaceutical products, and botanical antibiotic and OTC TCMsthrough its network of over 3,000 distributors and over 70 sales centersacross 24 provinces in China. Company Website: http://www.renhuang.com
Safe Harbor Statement
This press release contains certain statements that may includeforward-looking statements within the meaning of the Private SecuritiesLitigation Reform Act of 1995. Such statements are based upon management'sbeliefs, assumptions and expectations of the Company's future operations andeconomic performance, taking into account the information currently availableto management. These statements are not statements of historical fact.Forward-looking statements involve risks and uncertainties, some of which arenot currently known that may cause actual results, performance or financialcondition to be materially different from the expectations of future results,performance or financial condition expressed or implied in any forward-lookingstatements. These forward-looking statements are based on current plans andexpectations and are subject to a number of uncertainties including, but notlimited to, the Company's ability to achieve its revenue and growth forecastfor Qing Re Jie Du Oral Liquid, the Company's ability to achieve its financialguidance, ability to continue to improve its days sales outstanding, abilityto list its shares on a senior stock exchange, ability to manage expansion ofits operations effectively, competition in the marketing and sales of itsproducts, and other factors detailed in the Company's annual report on Form10-K and other filings with the Securities and Exchange Commission. TheCompany undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events orotherwise. You are cautioned not to unduly rely on such forward-lookingstatements when evaluating the information presented herein.Company Contact: Renhuang Pharmaceuticals, Inc. Ms. Portia Tan, IR Contact Tel: +86-451-5392-5461 Email: [email protected]
CCG Investor Relations: Ms. Lei Huang, Account Manager Tel: +1-646-833-3417 (New York) Email: [email protected]
Web: www.ccgirasia.com Mr. Crocker Coulson, President Tel: +1-646-213-1915 (New York) Email: [email protected]
SOURCE Renhuang Pharmaceuticals, Inc.